Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

October 31, 2015

Study Completion Date

May 31, 2017

Conditions
Colorectal Cancer Metastatic
Interventions
DRUG

Sorafenib Plus Capecitabine (SorCape)

Sorafenib 200-400 mg PO twice daily on days 1-21 (dose escalation schema) plus Capecitabine 1000 mg/m2 PO twice daily on days 1-14 repeated every 21 days

Trial Locations (1)

32610

UF Health Cancer Center, Gainesville

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

University of Florida

OTHER